Literature DB >> 17347447

No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.

John P Clancy1, Steven M Rowe, Zsuzsa Bebok, Moira L Aitken, Ron Gibson, Pam Zeitlin, Pierre Berclaz, Rick Moss, Michael R Knowles, Robert A Oster, Nicole Mayer-Hamblett, Bonnie Ramsey.   

Abstract

Cystic fibrosis (CF) is an autosomal recessive disorder caused by many types of genetic defects, including premature stop codons. Gentamicin can suppress stop mutations in CF transmembrane conductance regulator (CFTR) in vitro and in vivo, leading to improvements in CFTR-dependent ion transport and protein localization to the apical surface of respiratory epithelial cells. The primary objective of this study was to test whether nasally administered gentamicin or tobramycin could suppress premature stop mutations in CFTR, resulting in full-length, functional protein. A secondary objective was to obtain data to aid in the design of multicenter trials using the nasal potential difference as a study endpoint. A multicenter study was conducted in two cohorts of patients with CF, those heterozygous for stop mutations in the CFTR gene and those without nonsense mutations, to investigate the effects of both gentamicin and tobramycin administered over a 28-d period on sequential nasal potential difference and airway cell immunofluorescence endpoints. Eleven patients with CF with stop mutations were enrolled in a randomized, double-blinded, crossover fashion to receive each drug, while 18 subjects with CF without stop mutations were randomized 1:1 in a parallel fashion to receive one drug. After demonstration of drug delivery, neither aminoglycoside produced detectable changes in nasal ion transport or CFTR localization in brushed cells from either study group. These results with first-generation suppressive agents suggest the need for improved drug delivery methods and/or more potent suppressors of nonsense mutations to confer CFTR correction in subjects with CF heterozygous for nonsense mutations. The study provides valuable information on parameters of the nasal potential difference measurements for use in future multicenter clinical trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17347447      PMCID: PMC1899350          DOI: 10.1165/rcmb.2006-0173OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  26 in total

1.  Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis.

Authors:  A Hamosh; B C Trapnell; P L Zeitlin; C Montrose-Rafizadeh; B J Rosenstein; R G Crystal; G R Cutting
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

Review 2.  Genotype and phenotype in cystic fibrosis.

Authors:  L C Tsui; P Durie
Journal:  Hosp Pract (1995)       Date:  1997-06-15

Review 3.  Genotype-phenotype correlations in cystic fibrosis.

Authors:  E Kerem; B Kerem
Journal:  Pediatr Pulmonol       Date:  1996-12

4.  Interactions of a small RNA with antibiotic and RNA ligands of the 30S subunit.

Authors:  P Purohit; S Stern
Journal:  Nature       Date:  1994-08-25       Impact factor: 49.962

5.  Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line.

Authors:  D M Bedwell; A Kaenjak; D J Benos; Z Bebok; J K Bubien; J Hong; A Tousson; J P Clancy; E J Sorscher
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

6.  In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis.

Authors:  M R Knowles; A M Paradiso; R C Boucher
Journal:  Hum Gene Ther       Date:  1995-04       Impact factor: 5.695

7.  Correlation between genotype and phenotype in patients with cystic fibrosis.

Authors: 
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

8.  Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials.

Authors:  Thomas A Standaert; Louis Boitano; Julia Emerson; Laura J H Milgram; Michael W Konstan; Janice Hunter; Pierre-Yves Berclaz; Lois Brass; Pamela L Zeitlin; Keith Hammond; Zoe Davies; Carla Foy; Peadar G Noone; Michael R Knowles
Journal:  Pediatr Pulmonol       Date:  2004-05

9.  Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations.

Authors:  M Howard; R A Frizzell; D M Bedwell
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

10.  The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae.

Authors:  B Bonetti; L Fu; J Moon; D M Bedwell
Journal:  J Mol Biol       Date:  1995-08-18       Impact factor: 5.469

View more
  32 in total

1.  An international randomized multicenter comparison of nasal potential difference techniques.

Authors:  George M Solomon; Michael W Konstan; Michael Wilschanski; Joanne Billings; Isabelle Sermet-Gaudelus; Frank Accurso; François Vermeulen; Elina Levin; Heather Hathorne; Ginger Reeves; Gina Sabbatini; Aubrey Hill; Nicole Mayer-Hamblett; Melissa Ashlock; John Paul Clancy; Steven M Rowe
Journal:  Chest       Date:  2010-05-14       Impact factor: 9.410

2.  Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.

Authors:  Venkateshwar Mutyam; Ming Du; Xiaojiao Xue; Kim M Keeling; E Lucile White; J Robert Bostwick; Lynn Rasmussen; Bo Liu; Marina Mazur; Jeong S Hong; Emily Falk Libby; Feng Liang; Haibo Shang; Martin Mense; Mark J Suto; David M Bedwell; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2016-11-01       Impact factor: 21.405

Review 3.  Biomarkers for cystic fibrosis drug development.

Authors:  Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2016-10-27       Impact factor: 5.482

4.  Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.

Authors:  Steven M Rowe; Ginger Reeves; Heather Hathorne; G Martin Solomon; Smita Abbi; Didier Renard; Ruth Lock; Ping Zhou; Henry Danahay; John P Clancy; David A Waltz
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

5.  Herbal dry extract BNO 1011 improves clinical and mucociliary parameters in a rabbit model of chronic rhinosinusitis.

Authors:  Do-Yeon Cho; Daniel Skinner; Calvin Mackey; Harold B Lampkin; Jeffrey Brent Elder; Dong Jin Lim; Shaoyan Zhang; Justin McCormick; Guillermo J Tearney; Steven M Rowe; Bradford A Woodworth
Journal:  Int Forum Allergy Rhinol       Date:  2019-01-18       Impact factor: 3.858

Review 6.  Targets for cystic fibrosis therapy: proteomic analysis and correction of mutant cystic fibrosis transmembrane conductance regulator.

Authors:  James F Collawn; Lianwu Fu; Zsuzsa Bebok
Journal:  Expert Rev Proteomics       Date:  2010-08       Impact factor: 3.940

7.  Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice.

Authors:  Mathilde Beka; Teresinha Leal
Journal:  J Vis Exp       Date:  2018-07-04       Impact factor: 1.355

8.  The effect of gentamicin-induced readthrough on a novel premature termination codon of CD18 leukocyte adhesion deficiency patients.

Authors:  Amos J Simon; Atar Lev; Baruch Wolach; Ronit Gavrieli; Ninette Amariglio; Ester Rosenthal; Ephraim Gazit; Eran Eyal; Gideon Rechavi; Raz Somech
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

9.  Progress in cystic fibrosis and the CF Therapeutics Development Network.

Authors:  Steven M Rowe; Drucy S Borowitz; Jane L Burns; John P Clancy; Scott H Donaldson; George Retsch-Bogart; Scott D Sagel; Bonnie W Ramsey
Journal:  Thorax       Date:  2012-10       Impact factor: 9.139

10.  Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model.

Authors:  Ming Du; Kim M Keeling; Liming Fan; Xiaoli Liu; David M Bedwell
Journal:  J Biol Chem       Date:  2009-01-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.